(redirected from vaso-occlusive crisis)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia.
Related to vaso-occlusive crisis: sickle-cell disease, acute chest syndrome, Sickle cell crisis
References in periodicals archive ?
Vaso-occlusive crisis, the most common complication of SCD, is an extremely painful, potentially deadly condition.
It usually decreases the rates of vaso-occlusive crisis and acute chest syndrome and the need for blood transfusions by 50% in adults.
The report provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease
Correlation Between Plasma Cell-Free DNA Levels and Inflammatory and Hemolytic Parameters in Sickle Cell Disease (SCD) Patients in Vaso-occlusive Crisis (VOC), SCD Patients in Steady State, Individuals With Sickle Cell Trait, and Healthy Controls (a) SCD Patients Crisis Steady State Parameters P r P r WBC, [10.
The most common clinical problem in SCD is the painful vaso-occlusive crisis resulting from blockage of small vessels.
Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease randomized controlled trial.
The number of vaso-occlusive crisis (VOC) events dropped 84%, 79%, 81%, 90%, and 74% during the five years of study, respectively (p=0.
Evaluating GMI-1070 in the treatment of individuals with sickle cell who have been hospitalized with vaso-occlusive crisis represents a critical next step towards potentially fulfilling an important medical need in this historically underserved patient population.
Vaso-occlusive crisis is observed to be the most common presentation in sickle cell anaemia.
The company said the HOPE Study, which is a pivotal Phase 3 clinical trial of GBT440 in people with sickle cell disease (SCD), will be conducted at leading SCD sites globally and is expected to enroll up to 400 adults and adolescents with SCD who have had at least one episode of vaso-occlusive crisis (VOC) in the previous year.
com)-- The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease.
GlobalData's clinical trial report, "Vaso-Occlusive Crisis Associated With Sickle Cell Disease Global Clinical Trials Review, H2, 2015" provides an overview of Vaso-Occlusive Crisis Associated With Sickle Cell Disease clinical trials scenario.